MGX
Metagenomi, Inc. Common Stock (MGX) 10Y Growth Potential Analysis (2026)
Overall Score
Growth
Revenue base remains very small at $0.36 per share, limiting scale.
No evidence of sustained top-line expansion in the provided TTM data.
Profitability
TTM margins are deeply negative, with EBIT margin at -6.9% and net margin at -6.9%.
Returns remain poor, with ROE at -63.6% and ROIC at -65.9%.
Financial Health
Liquidity is strong with a current ratio of 4.5x and cash ratio of 1.4x.
Leverage appears manageable, with debt-to-equity at 0.34x and net debt to EBITDA near zero.
Valuation
Valuation looks inexpensive on asset-based measures, with price-to-book at 0.39x and price-to-sales at 3.22x.
Cash-flow and earnings multiples are not meaningful because TTM operating cash flow and earnings are negative.
Momentum
No recent news or price-action evidence was provided to support positive momentum.
The current dataset does not indicate a catalyst for re-rating.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Metagenomi, Inc. Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.